MedImmune, Genentech Strike Deal In Synagis Case
Rival biotechnology companies MedImmune Inc. and Genentech Inc. have reached a deal in the patent suit over MedImmune's blockbuster drug Synagis, signaling the end of a dispute that led to the...To view the full article, register now.
Already a subscriber? Click here to view full article